Clinical Digest: Recent Clinical Trials on HIV (AIDS) (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to HIV (AIDS). These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on HIV (AIDS) (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics: The HIV Testing Services PrEP Integration (HTS PrEP) Project PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This is a cluster randomized, stepped wedge implementation study to introduce HIV testing services (HTS) counselor-led PrEP care in public health clinics in Kenya. |
KENNETH K MUGWANYA; | 2025-07-29 |
| 2 | STeroids and Enhanced Spectrum Antibiotics for The Treatment of Patients in Africa With Refractory Sepsis (STARS Trial) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Sepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa, particularly among people living with HIV. The current standard of care in the region, ceftriaxone, is insufficient as it does not address TB, drug-resistant bacteria, or adrenal insufficiency, which is common in HIV-related sepsis. Therefore, … |
SCOTT HEYSELL; | 2026-01-12 |
| 3 | Improving The Treatment of Depression Among Youth With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Depression is a common psychiatric condition among Youth with HIV (YWH), with prevalence as high as 25% in the United States. The treatment of depression is essential for improving both psychiatric and medical outcomes for YWH (e.g., adherence to antiretroviral treatment). Practice guidelines for the treatment of depression and substantial research (including for those with and without HIV), indicate that measured-care treatment (care decisions guided by systematic symptom measurement) and using a combination of a medication management algorithm (MMA) and cognitive behavioral therapy (CBT) that is tailored to the population is efficacious. Unfortunately, … |
LARRY K BROWN; | 2026-02-27 |
| 4 | Project SPEED – Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Project SPEED (Streamlined Protocol for Early Engagement and Delivery of HIV Prevention) is a pragmatic, cluster randomized implementation study evaluating a nurse-driven model for delivering long-acting injectable cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP) within local public health departments (LPHDs) in Missouri. Although LAI-CAB is a highly effective HIV prevention strategy, access remains limited in many rural and resource-constrained settings due to workforce shortages and barriers to specialty care. In this study, LPHDs are randomized to either implement a structured nurse-led PrEP delivery protocol (SPEED intervention) or continue current standard practices. At intervention sites, trained registered nurses assess PrEP eligibility, … |
KC CARE HEALTH CENTER | 2026-01-16 |
| 5 | A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess The Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Laryngopharyngeal Reflux (LPR) is a common condition that causes symptoms like chronic cough, throat clearing, hoarseness, and trouble swallowing. If not treated, LPR can lead to long-term throat damage and may increase the risk of throat cancer. More than 20% of the people in the United States are estimated to have LPR, yet there is no effective medication approved to treat it. Drugs called proton pump inhibitors (PPIs) are often used to treat LPR, even though they were designed for stomach acid problems. These medications reduce acid but do not stop reflux from happening, … |
NIKKI JOHNSTON; | 2026-02-09 |
| 6 | Curing HIV: Proof of Concept Randomized Clinical Trial With Pyrimethamine, Lenalidomide, TOpiramate PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies (shock and kill’ strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger immune recognition, and facilitate the elimination of reservoir cells. Participants of the trial are adults with HIV with undetectable viral load that are able to give informed consent to participate in the trial, in total 30 patients will be recruited. The investigational medical compounds in this trial are topiramate, lenalidomide and pyrimethamine, … |
CASPER ROKX; | 2026-02-03 |
| 7 | Prevention of Recurrence of Herpes Simplex in Patients With Autoimmune Rheumatic Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate the effectiveness and safety of oral suppressive therapy with acyclovir in preventing herpes simplex virus (HSV) reactivation in patients with autoimmune rheumatic diseases (ARDs) who have a history of recurrent HS episodes. The main questions this study aims to answer are: Does continuous oral acyclovir reduce the frequency of HSV reactivation in ARD patients compared to placebo? What is the safety profile of prolonged acyclovir use in this population? What are the main risk factors (clinical and treatment-related) associated with HSV reactivation in immunosuppressed patients. Participants will: Be randomly assigned (1:1) to receive oral acyclovir (400 mg BID) or placebo for 12 months; Be followed for a total of 24 months, with regular clinical evaluations (every 3 months) and laboratory monitoring (every 3 months); Be assessed for HSV recurrence based on clinical symptoms, detection of HSV DNA by polymerase chain reaction (PCR) in mucocutaneous swabs in doubtful cases, and standardized reporting forms; Undergo disease activity assessments and adverse event monitoring at regular intervals. The study includes adult and pediatric patients with confirmed diagnoses of one of the following ARDs: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), dermatomyositis/polymyositis (DM/PM), systemic sclerosis (SSc), systemic vasculitis, primary Sjögren’s syndrome, Mixed connective tissue disease (MCTD), Chronic recurrent multifocal osteomyelitis (CRMO), Sarcoidosis and Behçet’s Syndrome. All participants must have a documented history of recurrent HSV (oral and/or genital) before inclusion. |
UNIVERSITY OF SAO PAULO GENERAL HOSPITAL | 2026-03-05 |
| 8 | The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this pilot trial is to investigate the feasibility of undertaking a randomized controlled trial involving adults living with HIV. Additionally, this trial will explore potential change differences in self-reported quality of life and blood-derived immune markers between a chiropractic care group and no treatment controls. |
TYSON PEREZ; | 2026-03-12 |
| 9 | A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate The Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing A Treatment Interruption of ≥12 Weeks PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person’s health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, … |
JESSICA ALTAMIRANO; | 2026-03-31 |
| 10 | Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects. |
J. LUCIAN DAVIS; | 2026-03-20 |
| 11 | Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV (SPISE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This observational research study is studying how substance use impacts scarring and inflammation of the heart. This study involves one study visit for a cardiac MRI. |
PHYLLIS TIEN; | 2026-03-10 |
| 12 | MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels AMong Congolese PregnAnt WoMen Attending to Ante Natal Care Consultations PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis. |
MAINDO ALONGO; | 2026-02-05 |
| 13 | Resilient HIV Implementation Science With SGM Youths Using Evidence PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a youth-tailored digital health platform. It is hypothesized that SGM youths in the HMP intervention group will demonstrate improved PrEP initiation and viral load suppression over 12 months compared to the delayed HMP group. |
MAN CHARURAT; | 2026-02-10 |
| 14 | Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic. With cervical cancer being a leading cause of cancer-related deaths in women living with HIV, and cervical cancer deaths being preventable through screening and early detection, this project seeks to identify factors associated with the successful implementation of the Screen, Triage, and Treat approach to inform future implementation and scale-up. |
REBECCA SCHNALL; | 2026-02-04 |
| 15 | Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH. The proposed study will evaluate the feasibility, acceptability, … |
MARGARET M. MADELEINE; | 2026-03-12 |
| 16 | An Investigation in The Use of Curcumin Topical Herbal Agent for The Treatment of Cervical Intraepithelial Neoplasia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology. |
LISA FLOWERS; | 2025-10-29 |
| 17 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for The Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD. Researchers will compare resmetirom to placebo (a look-alike substance that contains no drug) to see if resmetirom decreases the amount of fat in the liver. Participants will: * Complete 3 screening visits to determine eligibility. * Take resmetirom or placebo every day for 24 weeks if eligible. * Have 2 MRI scans to measure the amount of fat on the liver. One will be before treatment starts and one will be at the end of 24 weeks of treatment. * Attend 3 scheduled clinic visits while on treatment for bloodwork and safety assessments. * Participate in 3 phone calls while on treatment and one phone call 4 weeks after treatment is completed to check for safety and any health changes. |
NAGA P. CHALASANI; | 2026-02-03 |
| 18 | Baricitinib Curative Repression of HIV-1 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug. |
VINCENT MARCONI; | 2026-02-23 |
| 19 | Adaptation and Implementation of An Evidence-based Approach to Advance HIV Prevention and Care PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Transgender women in the intervention condition will attend TransAction individual risk reduction sessions; skill building and open group support sessions, and social events between baseline and 3-month assessment. Transgender women participants in the control condition will be invited to social events only. |
CHUNQING LIN; | 2026-03-27 |
| 20 | An Exploratory Clinical Study of The Safety and Efficacy of YTS109 Cell Injection in Children With Relapsed/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This exploratory, single-arm, open-label study will evaluate the safety and preliminary efficacy of YTS109 cell therapy in pediatric patients with relapsed/refractory autoimmune diseases, including systemic lupus erythematosus, diffuse systemic sclerosis, idiopathic inflammatory myopathies, and Sjögren’s syndrome, … |
CHILDREN’S HOSPITAL OF FUDAN UNIVERSITY | 2026-02-27 |
| 21 | Attitudes of Dental Students Towards HIV+ Patients: A Multi-center Survey Among Italian Universities PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this multicentric study was to assess the attitude of Italian dental students towards HIV-infected patients. In particular, the level of discomfort perceived during the treatment, any discriminatory attitude on their part, their level of knowledge of the disease and the application of the sterilization protocols to avoid professional exposure and cross-infections. |
LAJOLO CARLO; | 2026-03-20 |
| 22 | A Randomized, Controlled Trial Assessing The Effects of Cognitive Behavioral Therapy to Prevent Worsening Insulin Resistance in Depressed, Virologically-Suppressed, Antiretroviral-Treated Adults With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment. Researchers will compare an internet-based (online) depression treatment program called cognitive behavioral therapy with depression education. In the online group, participants will undergo 9 weekly treatment sessions. The education group will receive learning materials about depression and will be monitored every month. All participants will have 4 study visits over 12 months. |
SAMIR K. GUPTA; | 2026-02-09 |
| 23 | Describe and Evaluate The Impact of Polypharmacy on Healthy Aging in People Living With HIV Over The Age of 75 Who Are Being Treated at Nice University Hospital PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, … |
CENTRE HOSPITALIER UNIVERSITAIRE DE NICE | 2026-02-05 |
| 24 | Syndemic Triple HIV/HBV/HCV Virus Screening Via EMR Automation at Primary Care Clinics PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Design: This will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Study participants will be primary care providers. For each participating provider, their encounter will be randomized to either control (no alert; no changes to EMR interface) or an alert with triple-testing order panel intervention arm (alert linked to order panel with screening tests for all three bloodborne viruses (BBVs) selected by default; … |
MAMTA K. JAIN; | 2025-12-15 |
| 25 | To Explore The Efficacy and Safety of Double-dose Third-generation EGFR-TKI Combined With Bevacizumab and Intrathecal Chemotherapy in Advanced NSCLC Patients With Progressive Leptomeningeal Metastasis After Prior Standard-dose Third-generation EGFR-TKI Treatment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis that progressed after prior standard-dose third-generation EGFR-TKI treatment. It also aims to investigate the correlation between cerebrospinal fluid genetic characteristics and prognosis as well as subsequent efficacy prediction in patients with leptomeningeal metastasis after resistance to standard-dose third-generation EGFR-TKI. The main questions it intends to answer are: Does this combined treatment regimen improve leptomeningeal metastasis response rate (LM-ORR) evaluated by RANO-LM? What adverse events occur in patients during the treatment with this combined regimen? Researchers will conduct a single-arm phase II prospective study to assess the effectiveness and safety of the combined treatment, without a control group comparison. Participants will: Receive double-dose third-generation EGFR-TKI (osimertinib 160mg qd, furmonertinib 160mg qd, or almonertinib 220mg qd) + intrathecal pemetrexed (induction phase: 10mg twice a week for 4 weeks; maintenance phase: 10mg once a week for 4 weeks; consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity) + bevacizumab 7.5mg/kg. Undergo screening assessments within 28 days before enrollment, including tumor imaging, laboratory tests, and cerebrospinal fluid examination. During the treatment period, conduct regular checkups and tests (such as blood routine, blood biochemistry, electrocardiogram, and imaging examinations) according to the protocol (once every 4 weeks in the first two treatment cycles, then once every 8 weeks). Complete quality of life assessment using the QLQ-C30 scale every 4 weeks and record changes in neurological symptoms and ECOG scores. |
SECOND AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY | 2026-02-10 |
| 26 | Engaging Pharmacists to Advance Tobacco Treatment Service Delivery for People Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This research will test the effects of a novel program (ENHANCE-TTS) with tools, training, and clinic facilitation support that capitalizes on pharmacists’ roles by expanding their scope of practice to deliver tobacco treatment. This effectiveness-implementation study will evaluate the effects of the ENHANCE-TTS program on implementation outcomes and patient-level smoking cessation outcomes in people living with HIV and concurrently identify key barriers and facilitators to implementing this program in practice. |
ALANA ROJEWSKI; | 2026-04-03 |
| 27 | Evaluation of Long-Acting Injectable (LAI) and Teen Clubs in Adolescents (ATTUNE) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a 2-stage study assessing the effect of peer navigation (support from peers) and long-acting injectable antiretroviral therapy (ART) on viral suppression and retention in care among adolescents living with HIV and receiving care in South Africa. |
MOHERNDRAN ARCHARY; | 2026-04-03 |
| 28 | A Phase I First-in-human Clinical Trial to Evaluate The Safety, Pharmacokinetics, and Antiviral Activity of The Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV). This study will also test the anti-viral activity of BNT351 in people living with HIV (PLWH) with detectable virus levels. The main goals of this study are: * To learn about the safety of BNT351 and check for side effects. * To measure the amount of BNT351 antibody in blood over time. * To test the amount of HIV in the blood at different times after treatment with BNT351 in people living with HIV. |
BIONTECH SE | 2026-03-19 |
| 29 | Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: A Cluster Randomized Trial (CASCADE-3001-A) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE) -3001-A trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering HPV self-collection for cervical cancer screening to eligible WLWH. The ‘CASCADE’ Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, … |
JENNIFER SMITH; | 2026-02-27 |
| 30 | Secondary Cervical Cancer Prevention of Vulnerable Women With Human Papillomavirus (HPV) and Human Immunodeficiency Virus (HIV) Co-infection in India PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; … |
ADELINE NYAMATHI; | 2026-02-23 |
| 31 | Long-Acting Cabotegravir And Rilipivirine In People Living With HIV-1 Subtype A6. A Multicentre Real-world, Retrospective Matched Case Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is common in Eastern Europe and among people who acquired HIV in that region, and on comparison with individuals with subtype B and those with an unknown subtype. Although long-acting cabotegravir and rilpivirine are widely used and effective, … |
POMERANIAN MEDICAL UNIVERSITY SZCZECIN | 2026-01-27 |
| 32 | Clinical Study on The Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in The Treatment of Acute Ischemic Stroke PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I/II, randomized, double-blind, placebo-controlled, single/multiple ascending dose clinical study (Investigator-Initiated Trial, IIT) evaluating the safety and efficacy of Human Adipose-Derived Stem Cell Exosomes (ADSC-exo, STX11102 Nasal Spray) in treating acute ischemic stroke (AIS). The study consists of two sequential parts: a Single-Ascending Dose (SAD) study and a Multiple-Ascending Dose (MAD) study. The SAD part will enroll 12 subjects with mild stroke (NIHSS 1-4). They will be sequentially enrolled into three dose cohorts (4 subjects each: 2×10⁹, 4×10⁹, and 8×10⁹ particles/mL) to receive a single nasal spray dose alongside standard care, … |
YUNCHENG WU; | 2026-02-10 |
| 33 | HIV, Equity, and Addiction Training (HEAT) Program PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama. |
ELLEN EATON; | 2026-02-18 |
| 34 | Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will refine and pilot test the Peer-led Dynamic Choice HIV Prevention (DCP) intervention in a single-arm pilot trial. The study will test the hypothesis that the Peer-led Dynamic Choice HIV Prevention intervention will be feasible and increase biomedical HIV prevention coverage in the 6 months after receipt of the Peer-led DCP intervention compared to the standard of care in the 6 months prior to intervention implementation. |
CATHERINE KOSS; | 2026-02-05 |
| 35 | Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Antiretroviral viral therapy (ART) allows people with human immunodeficiency (HIV) to live long, healthy lives. But ART is not a cure. HIV can remain in the body, in infected cells called reservoirs. If a person stops taking ART, the HIV can rebound and reach high levels in their blood. Researchers want to find ways to reduce the size of HIV reservoirs in people taking ART. Objective: To test a drug (lenacapavir) in people with HIV who are on effective ART. Lenacapavir, also called Sunlenca, … |
CHUEN-YEN C LAU; | 2026-03-30 |
| 36 | Universal Test and Connect for HIV Service Delivery in South Africa and Baltimore PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to determine how many patients with HIV or at high risk of getting HIV attend the Emergency Department (ED) in South Africa (SA). The investigators will integrate HIV assessment in the ED and see how many people who would be a candidate for a drug that prevents HIV (PrEP). Universal test and connect (UTC) is a strategy that universally tests all patients and connects patients to long-term care, whether HIV positive or negative, including referrals for PrEP. The investigator’s goal is to use UTC across two busy 24-hr EDs in Cape Town, SA. |
BHAKTI HANSOTI; | 2026-01-30 |
| 37 | Piloting AI-Delivered Dialectical Behavioral Therapy for Suicide Prevention in Older Patients Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, … |
ELISSA KOZLOV; | 2026-01-15 |
| 38 | A Hybrid Type III Effectiveness – Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique. |
D. TROY MOON; | 2025-12-17 |
| 39 | A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on The Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in The Treatment of Guillain-Barre Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Guillain-Barre syndrome is an immune-mediated acute inflammatory peripheral neuropathy. The currently effective treatment methods include intravenous immunoglobulin and plasma exchange. Immunoadsorption has been widely used to treat immune-related diseases. There are currently no prospective large-sample clinical trials of immunoadsorption therapy for Guillain-Barre syndrome. The neuro-intensive care unit of the First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, … |
WANG MIAO; | 2025-03-12 |
| 40 | The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will use focus group methodology in the formative evaluation phase. Focus group methodology provides a rich source of data and understanding of phenomena by allowing the researcher to examine the interaction among participants |
IJEOMA OPARA; | 2025-10-09 |
| 41 | A Clinical Study Evaluating The Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2026-01-20 |
| 42 | MyPEEPS Mobile Plus PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: MyPEEPS Mobile Plus, a multi-level intervention for improving HIV prevention outcomes in YMSM, is a novel and evidence-driven approach using mobile technology to deliver HIV prevention information specifically developed for YMSM. Building on strong preliminary work, the proposed research is the next logical step in a body of work designed to assess whether refinement of this mobile intervention used in combination with virtual PrEP Peer Navigation will result in improvements in PrEP uptake and a reduction in HIV-related behavior. This is key to advancing HIV prevention among HIV-negative US persons at extremely high-risk for HIV seroconversion. |
REBECCA SCHNALL; | 2025-09-29 |
| 43 | Feasibility and Acceptability of The Promoting Resilience in Stress Management (PRISM) Intervention Among Adolescents (10 – 19 Years) Living With HIV in Eswatini: A Single Site, Single-Blind, Randomized Controlled Pilot Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Adolescents living with Human Immunodeficiency Virus (ALHIV) are at an increased risk of experiencing psychological distress and adverse mental health outcomes, particularly in low- to middle-income countries (LMICs). Although interventions aimed at promoting resilience have demonstrated potential in enhancing psychosocial outcomes among adolescents with chronic illnesses in high-income settings, there is a paucity of evidence from LMICs. This study protocol aims to outline a comprehensive framework for evaluating the feasibility, acceptability, and effectiveness of the Promoting Resilience in Stress Management (PRISM) intervention in comparison to standard psychosocial care among ALHIV in a LMIC, … |
MUSA LEWIS NHLABATSI; | 2025-12-04 |
| 44 | A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate The Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV-1 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, … |
MERCK SHARP & DOHME | 2026-03-27 |
| 45 | OPTImizing Malaria And HIV Treatment in A Shifting Landscape in Africa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline. |
SUNIL PARIKH; | 2026-02-04 |
| 46 | ALPCO Syphilis-T and Syphilis-NT CLIA Kits: Detection of Antibodies to Treponema Pallidum and Against Lipoidal Antigens in Human Serum and Plasma PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit. These kits are designed to detect antibodies to Treponema pallidum and non-treponemal lipoidal antigens, respectively, in human serum and plasma using the automated KleeYa platform. The study will collect and analyze blood samples from individuals suspected of having syphilis, those at high risk, HIV-positive patients, pregnant individuals, and healthy controls. The aim is to determine the kits’ Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) compared to established reference assays. |
AMERICAN LABORATORY PRODUCTS COMPANY | 2026-02-11 |
| 47 | Unveiling The Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance. |
ASMAA NADY HUSSEIN; | 2025-08-14 |
| 48 | Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to understand the implementation requirements and potential health impacts of a guaranteed income (GI) intervention targeting people living with HIV with criminal legal involvement (PWH-CLI). The main questions it aims to answer are: * How acceptable is a GI intervention, and its intervention components, … |
PAUL D WESSON; | 2026-03-13 |
| 49 | Clinico_Epidemiological Profile Of Acquired Aplastic Anemia Among Children At Assiut Governorate PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: 1. Assessment the clinical presentation and epidemiological profile of children with acquired aplastic anemia. 2. Determining the possible risk factors and associated conditions contributing to the development of acquired aplastic anemia. |
SARA RAMADAN HASSANEIN HASSAN; | 2025-12-02 |
| 50 | Association Between Inflammation Biomarkers and Neurocognitive Performance Among Adolescents Living With HIV in Eswatini PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study explores the link between inflammatory biomarkers and neurocognitive performance in adolescents living with HIV (ALHIV) in Eswatini. Persistent HIV infection during adolescence has been associated with ongoing systemic inflammation and subsequent neurocognitive dysfunction. However, the exact nature of this relationship is not well-defined, especially in resource-limited settings where epidemiological and mechanistic data are scarce. objectives * To determine the prevalence of cognitive impairment among a sample of adolescents living with HIV, … |
PHATHIZWE M MANTSHANA; | 2025-09-15 |
| 51 | An Exploratory Pharmacodynamic Clinical Study of CL-197 Capsules in Treatment Naive Patients With Human Immunodeficiency Virus (HIV-1) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection. |
HENAN GENUINE BIOTECH | 2026-01-06 |
| 52 | Harnessing Data Science to Improve HIV Care Continuum Outcomes: A Hybrid Type 2 Trial Evaluating A Machine-Learning Algorithm-Based Implementation Strategy PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study tests a strategy for helping Care Management Agencies prioritize patients with HIV (PWH) for outreach and support. Under the new strategy, care managers are given a list of highest-priority patients who have been identified by a computer algorithm as being at high risk of going to the emergency room in the next two weeks. This strategy is compared to traditional (standard of care) care management, … |
SARIT GOLUB; | 2026-01-27 |
| 53 | Self-sampling to Optimize Anal Lesion Outcomes (SOLO) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this research study is to find ways to increase anal cancer screening among people at increased risk for anal cancer. This study will try to find out if persons will do an intervention (self-sampling of the anal canal) and if it affects cytology and high-resolution anoscopy (HRA) appointment attendance. Secondarily, the study will assess if a person who gets their choice of either self-sampling or healthcare provider sampling affects clinic attendance. |
ALAN NYITRAY; | 2026-01-12 |
| 54 | The SUSTAIN 2 Study – SUStained HIV Treatment for Adherence After Interruption in Care PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if the DSD model (SUSTAIN-DSD) is effective in improving participants HIV treatment adherence. The main questions it aims to answer are: * Does the SUSTAIN-DSD intervention significantly improve participants’ treatment adherence and increase rates of viral suppression? * Does the SUSTAIN-DSD intervention help retain people in care? * Does SUSTAIN-DSD intervention help reduce the length of treatment interruptions? * for 24 months, … |
INGRID THERESA KATZ; | 2025-11-24 |
| 55 | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective cohort study of 12 overweight (with one or more weight-related condition) or obese adults with well controlled HIV-1 on antiretroviral therapy (ART). An initial dose of tirzepatide (TZP) 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg. The investigators will collect the following information via review of the medical record: age, race/ethnicity, sex, medical conditions, medications, … |
CHRISTINE AKAMINE; | 2025-11-28 |
| 56 | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate The Efficacy and Safety of MK-8527 Oral Once-Monthly As HIV-1 Preexposure Prophylaxis in Women PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it |
MERCK SHARP & DOHME | 2026-03-30 |
| 57 | Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Adolescents and Young Adults (Project IMPACT) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk. |
MATTHEW MIMIAGA; | 2026-01-12 |
| 58 | Reducing Stigma in People Who Inject Drugs With HIV Using A Rapid Start Antiretroviral Therapy Intervention (RS-ART) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART. This strategy will then be pilot tested in a randomized controlled trial (Aim 3). The research will not impact the type of medication and dose prescribed, but rather, how soon providers are able to prescribe ART after diagnosis. The focus of this registration is Aim 3. |
FREDERICK L ALTICE; | 2026-01-29 |
| 59 | Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men – A Danish Prospective Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The incidence of anal cancer is increasing, particularly among high-risk groups such as men who have sex with men (MSM), especially those living with HIV. The lack of comprehensive screening programs results in delayed diagnosis and higher mortality. This project aims to establish a screening program for anal cancer in high-risk populations, with a specific focus on those most at risk. Using a prospective study design, the project will assess the effectiveness of early detection and prevention strategies to potentially reduce cancer incidence and improve survival rates. If an HPV-based screening method proves effective, … |
HELLE KIELLBERG LARSEN; | 2025-08-14 |
| 60 | Phase I Dose Escalation Study of The Use of ACU-D1, A Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions. The main questions it aims to answer are: * The maximum tolerated dose of ACU-D1 * Safety and tolerability of topical ACU-D1 * Whether topical ACU-D1 induces p53 and p53-mediated downstream signaling (including p21 induction) in HPV-related lesions * Whether topical ACU-D1 enhances markers of immunity in HPV-infected HIV-positive individuals Participants will be asked * To apply ACU-D1 on the lesions twice daily for 4 weeks * 3 biopsies will be performed at the screening and 3 at the end of 4 weeks. |
LISA FLOWERS; | 2025-08-06 |
| 61 | A Single-Center, Open-Label, Randomized, Crossover Phase I Clinical Study to Evaluate The Pharmacokinetics and Bioequivalence of Two Different Formulations of HMPL-523 Acetate Tablets in Chinese Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy. This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans. |
HUTCHMED | 2026-02-12 |
| 62 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study involves patients that have a cancer called diffuse large B cell lymphoma (DLBCL), Natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma). Patients’ lymphoma has come back or not gone away after treatment. A previous research study at Baylor combined two ways of fighting disease: antibodies and T cells. Antibodies are proteins that bind to bacteria, viruses and other foreign substances to prevent disease. T-cells are special infection-fighting white blood cells that can kill tumor cells or cells infected with bacteria and viruses. Both have shown promise treating cancer, … |
PREMAL LULLA; | 2025-11-13 |
| 63 | Reducing The Intersecting Stigmas of HIV, Violence Victimization, and Mental Health: A Randomized Controlled Pilot Integrating Project YES! Youth Engaging for Success With WHO-Endorsed Mental Health Approaches Among Youth Living With HIV in Ndola, Zambia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The proposed study will address the intersecting stigmas of HIV, violence and depression among adolescents and young adults (15-24) living with HIV (AYALHIV) in Zambia. The study will integrate a WHO-endorsed mental health approach into an existing HIV-stigma-reducing intervention, and refine measures of internalized and intersecting stigmas, to create and test the feasibility of Project YES+- a combined youth peer mentoring and lay mental health intervention. This research aims to shift HIV care and treatment for AYALHIV by addressing the multiple internalized and intersecting stigmas that impeded antiretroviral adherence and HIV viral suppression. |
JULIE A DENISON; | 2025-11-24 |
| 64 | New And Recurrent Visceral Leishmaniasis in HIV Co-Infected Ethiopian Patients: A Cohort Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target group in Ethiopia |
ELENI AYELE; | 2026-03-23 |
| 65 | A Single-Arm, Open-Label Clinical Phase II Trial of The Safety and Immunogenicity of PDS0101 in People Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is testing the immunotherapeutic agent, PDS0101, in adults living with HIV who are also infected with human papillomavirus (HPV) type 16. The purpose of the study is to learn whether PDS0101 is safe and whether it can help the body’s immune system respond to HPV 16. Researchers will enroll 27 adults between the ages of 25 and 65 who have been receiving antiretroviral therapy (ART) for at least 12 months, have a cluster of differentiation 4 (CD4) cell count of at least 200 cells/mm³, … |
GRANT ELLSWORTH; | 2025-10-01 |
| 66 | Promoting Aging and Thriving With HIV (PATH)-Implementation of A Tailored Geriatric Assessment and Management Strategy for HIV Care Settings PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The pilot is an intervention of a geriatric assessment and management tool (PATH) in outpatient HIV clinics. |
MEREDITH GREENE; | 2025-12-19 |
| 67 | Identifying and Addressing Barriers to Retention in The Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators will conduct the formative work that is necessary to develop a novel, multi-level intervention (inclusive of patient- and provider-level components), which will increase awareness of and modify the complex, intersecting factors that contribute to cervical cancer development among cisgender women with HIV (WWH). In Aim 1a, the investigators will explore the multi-level barriers and facilitators to follow-up appointment attendance among WWH who have had a recent high-risk abnormal Pap smear in the past six months, … |
AMELIA M. STANTON; | 2025-09-19 |
| 68 | Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing (S-ITEST), locally known as 4 Youth by Youth (4YBY) in Nigeria, builds on the investigator’s previous efforts, which are detailed in ClinicalTrial ID#: NCT04070287, NCT03874663, and NCT04710784. Many adolescents and young adults (AYA, 14-24 years old) in Nigeria have a substantial HIV risk but do not receive adequate HIV prevention services. While pre-exposure prophylaxis (PrEP), HIV self-testing, sexually transmitted infection (STI) testing, and linkage to AYA-friendly clinical services are essential, they have not been widely implemented or sustained in Nigeria. In this study, the investigators aim to 1) use participatory approaches (i.e., … |
JULIET IWELUNMOR; | 2025-10-29 |
| 69 | Voluntary HIV Screening in The General Population in France PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed. Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening. |
UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE | 2026-02-18 |
| 70 | IGHID 12430 – Deliver-02 – A Phase 1, Open Label, Randomized Study To Evaluate The Safety And Tolerability Of MGD014 And MGD020 With A Latency Reversal Agent Versus Temporary Treatment Interruption In Persons With HIV-1 On Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, … |
CYNTHIA L. GAY; | 2025-12-12 |
| 71 | #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The #aware.hiv Europe study is a real-world, multicenter, stepped-wedge cluster randomized, effectiveness-implementation trial designed to evaluate whether the introduction of dedicated HIV teams in hospitals can improve HIV testing rates among patients presenting with HIV indicator conditions across ten European countries. Study Design: The study employs a stepped-wedge design, whereby clusters of hospitals transition sequentially from a control phase (routine care) to an intervention phase. All patient data are collected retrospectively from routine care, while prospective data are gathered at the healthcare professional level. The project spans four years and involves hospitals from the Netherlands, Belgium, United Kingdom, Germany, Spain, … |
CASPER ROKX; | 2026-03-12 |
| 72 | Using Artificial Intelligence Models for Predicting The Need for Intubation and Successful Weaning From Mechanical Ventilation in ICU Patients PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Using artificial intelligence (AI) approach to build a model to determine the optimal timing of intubation and optimal timing of weaning from MV for ICU patients, and compare outcomes with these which depend on clinicians dicision. And also assess whether AI-assisted decisions improve patient outcomes (e.g., reduced intubation delays, shorter ventilation duration). |
FATEMA MEDHAT AHMED; | 2025-07-15 |
| 73 | Optimizing Pan-Viral Screening and Linkage to Treatment and Vaccination Among GBMSM and Trans Women in Spain, Including PrEP Users and Those Awaiting Access: An Online Self-Sampling Pilot Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality. However, hepatitis C virus (HCV) transmission has increased among gay, bisexual, and other men who have sex with men (GBMSM), especially those living with HIV. Practices such as chemsex, particularly involving injection drug use, have contributed to this rise. Hepatitis B virus (HBV) also remains a public health challenge due to the potential for chronic infection and severe liver damage. Hepatitis D virus (HDV), which requires HBV co-infection, … |
FUNDACIÓ INSTITUT GERMANS TRIAS I PUJOL | 2025-07-25 |
| 74 | Reducing Systemic Inflammation in People on Antiretroviral Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone. |
MADELEINE DURAND; | 2025-11-19 |
| 75 | Comparison of The Body Roundness Index and A Body Shape Index With Body Fat and Visceral Fat in People Living With HIV: A Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study compares the Body Roundness Index (BRI) and the A Body Shape Index (ABSI) with with body fat and visceral fat in people living with HIV. |
NORBERTO QUILES; | 2025-10-02 |
| 76 | A Randomized, Open-label Clinical Trial to Assess The Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy. |
STEPHANIE GAILLARD; | 2025-10-15 |
| 77 | A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate The Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-02-17 |
| 78 | Conducting An Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests The Potential for Clinical Benefits of HIV (+) Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1. Treat Infection of Multiple Gene Mutation HIV Virus Strains. 2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly. |
HAN XU; | 2025-10-07 |
| 79 | An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed/refractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers. This therapy is based on collecting the patient’s own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, … |
HEALTH INSTITUTES OF TURKEY | 2026-03-30 |
| 80 | Impact of Breast Milk on The Infectivity and Transmission of Different Viruses BREASTMILKVIR PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Exclusive breastfeeding during the first six months of life and continued breastfeeding for at least 24 months constitute the optimal feeding method for infants and young children. However, breast milk and breastfeeding can be significant pathways for the transmission of certain viruses. The objective of this study is to examine the influence of human breast milk and its composition on viral infectivity and viral transmission of the HTLV-1 virus and arboviruses such as Zika virus, yellow fever, dengue, and tick-borne encephalitis. |
VIRGINIE RIGOURD; | 2025-12-15 |
| 81 | The Integrated Female Sexually Transmitted Infection Testing for HIV Epidemic Control Through PrEP (IN-STEP) Study PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Globally, new HIV infections are concentrated in eastern and southern Africa where the infections are largely acquired by women outside of known key populations. Identifying African women at high risk for HIV acquisition and successfully engaging them in HIV prevention services, particularly pre-exposure prophylaxis (PrEP) programs, is an urgent global health priority. The U.S. President’s Emergency Plan for AIDS Relief program in Africa typically relies on self-reported risk screening tools (SRST) to target HIV testing and refer individuals for PrEP. However, these tools have low to moderate sensitivity, … |
MARY KATHRYN GRABOWSKI; | 2025-09-15 |
| 82 | An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PJP) in Non-HIV Immunocompromised Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and alleviating the burden on families and society. To address this medical challenge, our institution is conducting a study aimed at lowering PJP-related mortality. Specifically, we are performing an adaptive, randomized, open-label controlled trial in patients with severe PJP. The primary objective of this study is to scientifically evaluate the efficacy and safety of adjunctive corticosteroids at different dosages, … |
QINGYUAN ZHAN; | 2025-09-09 |
| 83 | Integrating HIV Prevention With TB Household Contact Evaluation in Uganda (TB PrEP) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This household randomized implementation study assesses the implementation and effectiveness of home-based HIV self- testing and PrEP initiation versus standard clinic referral for PrEP initiation during modified standard-of-care (modified SOC) household TB contact investigation in Uganda. It uses qualitative methods to evaluate the process of implementing the intervention and a health economic evaluation to assess the financial sustainability of this strategy. |
JENNIFER ROSS; | 2025-08-13 |
| 84 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches. Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries. |
CHRISTINA CARLANDER; | 2025-07-10 |
| 85 | Optimal Stimulation of Hypo-responders Undergoing IVF: A Prospective, Randomized, Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Stimulation is a key step of in vitro fertilization (IVF). Typically, injectable gonadotropins are used for stimulation, and their dose is individually determined to avoid hypo- as well as hyper-response. Despite the individualization some patients respond with a lower-than-expected number of oocytes. If the low response is unexpected based on the baseline parameters or if an unusually high dose of gonadotropins is needed to achieve a proper response we talk about hypo-response. In such cases if the first treatment fails and a repeat attempt is planned typically even more gonadotropins, … |
PETER KOVACS; | 2025-08-13 |
| 86 | Wellness, Intervention Strategies and HIV Care PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a pilot trial designed to assess the feasibility and acceptability of an intervention aimed at improving adherence to antiretroviral therapy (ART), viral suppression, and engagement in HIV care. The intervention will address behavioral coping strategies, HIV care engagement behaviors, and substance use management. |
JENNIFER P JAIN; | 2026-01-27 |
| 87 | Role of Empagliflozin in Metabolic Changes Associated With Antiretroviral Therapy in Human Immunodeficiency Virus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: We investigate the role of empagliflozin in the treatment of obesity in PLWH. |
ABDELRAHMAN MAHMOUD; | 2026-01-13 |
| 88 | The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients Related Papers Related Patents Related Grants Related Experts Highlight: Autologous CAR-T cell therapy in HIV-1/AIDS patients |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2026-03-05 |
| 89 | Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention. |
CARA SPENCE; | 2025-10-07 |
| 90 | Hybrid Trial of A Digital Therapeutic for Smoking Cessation Among Persons Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, … |
ROGER VILARDAGA VIERA; | 2025-12-17 |
| 91 | BRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: BRAVO proposes the establishment of a comprehensive registry of chronic noncommunicable diseases (NCDs), providing crucial data for the formulation of effective health policies for people living with HIV/AIDS (PLWHA). The study will comprise a cross-sectional and longitudinal assessment: the cross-sectional study, will collect on the study allocation sociodemographic data, risk factors related to the main NCDs, physical examination data and samples for determination of biochemical and metabolic parameters; the longitudinal study, lasting 1 year and with the possibility of extension, will follow the participants to identify new diagnoses in the broad spectrum of NCDs. To this end, … |
VICTOR AUGUSTO HAMAMOTO SATO; | 2025-08-12 |
| 92 | Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients with chronic diseases, and elderly individuals) who receive their first post-exposure treatment following WHO category II or III rabies exposure. The control group will include 30 healthy adults with similar exposure. Blood samples will be collected at Day 14 and Day 90 after completion of the full vaccination schedule to assess rabies virus neutralizing antibody seroconversion rates and titers. Immunogenicity and antibody persistence will be compared between the two groups. Additionally, … |
FANG HUANG; | 2025-08-13 |
| 93 | V-IMMUNE® for Primary Immunodeficiency: A Phase III Clinical Trial (VIP Study) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, non-randomized clinical trial (VIP Study) designed to assess the safety and efficacy of V-IMMUNE®, a 5% human normal immunoglobulin preparation, in approximately 50 patients with primary immunodeficiency (PID). Participants, all aged ≥2 years and already receiving IVIG therapy, will be switched to V-IMMUNE® at a dose of 600 mg/kg every three weeks via intravenous infusion. The study will use historical data as a control and extend over 12 months, … |
DEWTON MORAES VASCONCELOS; | 2026-01-20 |
| 94 | Questioning The Epidemiology of Asymptomatic TB PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) remains one of the world’s leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the disease as the major drivers of the TB epidemic. However, prevalence surveys have shown that about 50% of cases in which Mycobacterium tuberculosis is isolated from sputum but do not report having symptoms. Therefore, asymptomatic TB may play an important role in TB transmission. However, … |
ALBERTO GARCIA-BASTEIRO; | 2025-12-31 |
| 95 | A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV: A Randomized Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this randomized clinical trial is to learn if tai chi/qigong decreases depressive symptoms among older people living with HIV compared to a health education class. The main questions it aims to answer are: Does tai chi/qigong reduce depressive symptoms among older people living with HIV more than a health education class? What are the behavioral, psychological, and biological mechanisms in which tai chi/qigong affects depressive symptoms? Does tai chi/qigong affect depressive symptoms among older people living with HIV differently for men compared to women? Researchers will compare a 12-week, … |
GLADYS IBANEZ; | 2025-09-08 |
| 96 | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate The Efficacy and Safety of MK-8527 Oral Once-Monthly As HIV-1 Preexposure Prophylaxis PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it |
MERCK SHARP & DOHME | 2026-03-30 |
| 97 | Developing A Digital-Based Education and Self-Screening Model to Improve Knowledge, Self-Awareness, and HIV Testing Coverage Among Adolescents PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn whether a digital tool can help improve HIV knowledge, self-awareness, and testing among adolescents in Yogyakarta, Indonesia. The tool includes online HIV education, a self-assessment for HIV risk, … |
RIZKA AYU SETYANI; | 2025-06-26 |
| 98 | Switch to Dolutegravir Plus Lamivudine Dual-therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy. |
MARTIN JAUME; | 2025-09-12 |
| 99 | Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya. |
ANDRE INWOLEY; | 2026-02-02 |
| 100 | VITAL Start (Video-Intervention to Inspire Treatment Adherence for Life) for Adolescents, A Randomized Controlled Trial of A Video Intervention to Improve Adherence, Retention, and Viral Load Suppression Among Adolescents Living With HIV PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This a two-arm randomized controlled trial whose objective is to explore the impact of VITAL Start for Adolescents (VS4A), a video-based antiretroviral treatment (ART) adherence intervention, on a range of implementation and effectiveness outcomes. The study will be conducted in health facilities which provide HIV care to teens/adolescents in the Machinga and Balaka districts of Malawi with approximately 900 teens living with HIV and their treatment supporters (dyads). Dyads will be individually randomized on a 1:1 ratio to receive either the intervention or the standard of care. The VS4A intervention is designed to support Information, Motivation, … |
SAEED AHMED; | 2025-07-25 |
| 101 | A Study to Evaluate The Performance of INSTI® HIV Self Test When Performed By Unobserved Intended Users in The US PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to evaluate the performance of INSTI® HIV Self Test with unobserved intended user population. The purpose of this study is to document if a lay person, unassisted by a healthcare worker, is able to perform the INSTI® HIV Self Test correctly and without significant risk of incorrect results. The study aims to evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV Self-Test in a lay user population. |
BIOLYTICAL LABORATORIES | 2025-08-20 |
| 102 | Mindfulness and Behavior Change to Improve Cardiovascular Health of Older People With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Older people with HIV (OPWH) are disproportionately impacted by cardiovascular disease (CVD) attributable to behavioral risk factors, and chronic HIV immune dysregulation resulting inflammation. Systemic inflammation is exacerbated by psychological distress via activating the immune response and driving pro-inflammatory CVD risk behaviors. There is promising evidence to suggest that mindfulness could be an effective intervention to reduce psychological distress and support behaviorally- … |
JACKLYN D. FOLEY; | 2025-09-22 |
| 103 | Efficacy, Safety, and Tolerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug Regimen With BIC/FTC/TAF or DTG/3TC/ABC in Virologically Suppressed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center La Raza. The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged ≥18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained virological suppression (HIV-1 RNA \<50 copies/mL) for at least 48 weeks. Participants will be randomized in a 2:1 ratio: 104 to switch to DTG/3TC and 52 to continue their current regimen (control group). |
JOSÉ ANTONIO MATA MARÍN; | 2025-08-22 |
| 104 | An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate The Impact of The Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on The Viral Reservoir in Adults Living With HIV-1 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). |
VIIV HEALTHCARE | 2026-03-24 |
| 105 | A Single Arm Open Label Phase 2 Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection Related Papers Related Patents Related Grants Related Experts Highlight: Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, … |
MICHAEL C SNELLER; | 2025-07-11 |
| 106 | Effectiveness of Ultrasonography-Guided Serratus Posterior Superior Intercostal Plane Block in Thoracic Postherpetic Neuralgia: A Retrospective Cohort Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Postherpetic neuralgia (PHN) is a chronic pain syndrome that can be resistant to treatment, leading to physical and social disability, psychological disturbances, and potentially persisting for years . The varicella-zoster virus remains latent in the sensory neurons of individuals who have previously contracted varicella (chickenpox). Reactivation of the latent virus results in herpes zoster (HZ). In most patients, HZ initially presents with dermatomal pain, and within a few days, characteristic dermatomal vesicular eruptions typically develop. These skin lesions usually heal within 2-4 weeks; however, … |
HALIL IBRAHIM ALTUN; | 2025-12-12 |
| 107 | Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in The Democratic Republic of The Congo PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be conducted in Boende, Tshuapa Province, DRC. A total of 359 maternal participants, aged 16 to 35 and in their second or third trimester of pregnancy, will be enrolled. Participants will be randomly assigned to receive two subcutaneous doses of the MVA-BN vaccine, given 28 days apart, … |
JEAN-PIERRE VAN GEERTRUYDEN; | 2026-01-30 |
| 108 | Massachusetts HIV and Justice Involved Populations Research Network PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This pilot feasibility study represents part 3 of a larger R61 study, where the investigators will follow a cohort about their experiences with human immunodeficiency virus (HIV) testing. This project aims to assess the effectiveness of an intervention at two jail sites in the Boston area: South Bay House of Corrections and Nashua Street Jail implemented in January of 2025 that is aimed at improving HIV testing practices and HIV treatment in those carceral facilities. This implementation was developed independently of the investigators’ study activities. The jails worked to develop changes in their electronic health record to offer HIV testing at various points in their intake and physical exam process. HIV care was not well-integrated with the jails’ existing intake and healthcare administration systems and medications for opioid use disorder (MOUD) program. The investigators will evaluate the intervention the jails developed to address these issues. The outcomes of interest are more implementation than effectiveness outcomes. The primary goal of this study is to identify existing barriers in the carceral healthcare setting that prevent the improvement of HIV testing and treatment. |
ALYSSE WURCEL; | 2025-07-30 |
| 109 | A Study of Spatially Fractionated Radiation Therapy Followed By Sequential Hypofractionated or Conventional Fractionated RT Combined With Iparomlimab and Tuvonralimab for Relapsed and Refractory Bulky Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Study Objectives Primary Objective:To evaluate the safety of SFRT followed by hypofractionated/conventional fractionated radiotherapy combined with Iparomlimab and Tuvonralimab Injection in relapsed/refractory bulky solid tumors. Secondary Objectives:To assess efficacy (objective response rate, disease control rate, progression-free survival, etc.) and identify predictive biomarkers.To explore correlations between immunologic biomarkers (e.g., PD-L1 expression, plasma IL-2/IL-10) and treatment outcomes. Study Endpoints Primary: Safety (incidence/severity of treatment-related adverse events). Secondary: ORR, DCR, DoR, mPFS, mOS Exploratory: Biomarker analysis (PD-L1, IL-2, IL-10). |
ANWEN LIU; | 2025-06-17 |
| 110 | Kisoboka: Reducing Hazardous Alcohol Use and Optimizing Treatment As Prevention Among Men Living With HIV in Risk Environments PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators developed the Kisoboka (It is possible) Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in risk environments such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads. Social and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, … |
SUSAN M KIENE; | 2025-06-17 |
| 111 | Feasibility, Acceptability, and Preliminary Efficacy of Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: An Open-Label Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD. |
E. JENNIFER EDELMAN; | 2026-03-24 |
| 112 | Development and Evaluation of A Multi-Component Intervention to Support HIV Testing and Linkage to Services Among Men Who Have Sex With Men (MSM) in Perú (PROJECT MERCURY) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is testing a new program designed to improve access to HIV testing and help connect people with available treatment or prevention services, based on their test result. The version of the program being tested in this study was designed for men who have sex with men (MSM) in Lima, Peru. The program has two main parts: 1) offering HIV testing at venues where people go for sex (called sex-on-premises venues or SOPVs), and 2) a text messaging app that shares useful information about HIV treatment/prevention; … |
ALEXANDER LANKOWSKI; | 2026-02-13 |
| 113 | Substance Use and HIV Action for Reentry and Engagement PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test a behavioral intervention with a case manager/peer navigator team pairing with clients to deliver transition planning services. The interactions help clients recognize and use their strengths. The goal is to see if this approach improves clients’ ability to access healthcare and drug treatment after being released from jail. |
ANNE C SPAULDING; | 2025-08-11 |
| 114 | Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures Outside The Walls By Dual Screening Method RTDs and FibroScan® PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The Scanvir concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient’s health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a test, treat and cure strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers. |
MARILYNE DEBETTE-GRATIEN; | 2025-08-14 |
| 115 | Impact of The COVID-19 Pandemic on Syphilis: Epidemiological Changes and Interaction With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Sexually transmitted infections (STIs) represent a significant challenge to global public health. Although many of these infections are treatable, failure to diagnose and delayed treatment can lead to serious complications, including infertility, chronic inflammatory diseases, and an increased risk of HIV transmission. The COVID-19 pandemic has had a significant impact on healthcare management, the economy, and citizens’ lifestyles. The first lockdown in the spring of 2020 affected the entire country, while in the following months, government measures were differentiated on a regional basis, with varying restrictions on activities and mobility. Physical distancing, the use of personal protective equipment, … |
AZIENDA OSPEDALIERA SS ANTONIO E BIAGIO E CESARE ARRIGO DI ALESSANDRIA | 2025-09-02 |
| 116 | Integration of Peer Health Navigation Into Comprehensive Re-entry Services: Improving PrEP Implementation for Justice-involved Individuals PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This 18-month study, Integration of peer health navigation into comprehensive re-entry services: improving PrEP implementation for justice-involved individuals, aims to increase PrEP awareness and uptake among people with a history of justice involvement in Dallas, primarily clients of Unlocking Doors. |
ANK NIJHAWAN; | 2026-01-15 |
| 117 | An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc. Aproximately 6-12 patients aged 18-65 will receive a single infusion of YTS109 cells (1.5×10⁶ cells/kg). The main purpose of exploratory clinical research is to explore the efficacy and safety of YTS109 cell and the lymphodepletion regimen. The primary endpoint is observations of types, severity, and frequency of adverse events (AEs) and efficacy assessment. This single-arm, open-label trial will enroll patients across Chinese People’s Liberation Army (PLA) General Hospital. |
CHINA IMMUNOTECH BEIJING BIOTECHNOLOGY | 2025-07-14 |
| 118 | Effect of Polyunsaturated Fatty Acids Omega-3 Supplementation on Pregnancy Outcomes and Inflammation Markers in Pregnant Women HIV+, With Antiretroviral Therapy, Randomized Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial aims to determine the effect of PUFA-n3 supplementation on birth weight, gestational length, and plasma inflammatory markers in pregnant women with HIV who are on antiretroviral therapy. The key questions this study seeks to answer are: 1. Will the neonates of HIV-positive women who received 1280 mg of PUFA-n3 supplementation during pregnancy have higher birth weights and longer gestation periods compared to the neonates of HIV-positive women who received a placebo? 2. Will the inflammatory markers in HIV-positive women who received 1280 mg of PUFA-n3 during pregnancy differ from those of HIV-positive women who received a placebo? Researchers will compare the effects of 1280 mg of PUFA-n3 supplementation against a placebo (olive oil) to determine if the supplement can increase birth weight, gestational length, and attenuate the inflammation. Participants in the study will: * Take a prenatal multivitamin that includes 300 mg of PUFA-n3 * Take either 1280 mg of PUFA-n3 or a placebo daily for 8 weeks, starting from a gestational age of 20-29 weeks. * Visit the hospital at the beginning of the study and again 8 weeks later for blood sampling. Additionally, they will have follow-up visits every 2 weeks to monitor gestational weight gain and dietary intake. * Keep a diary to register their supplement intake and record any side effects. |
ESTELA YTELINA GODÍNEZ MARTÍNEZ; | 2025-09-11 |
| 119 | Evaluation of Long-term Immunogenicity of A Boost Dose of MVA-BN Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine |
LIEM BINH LUONG NGUYEN; | 2025-05-15 |
| 120 | Advanced HIV Disease During The First Six Months on Antiretroviral Therapy in Zambia PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: In Zambia, an estimated 20% of HIV-positive clients continue to present for first-time antiretroviral therapy (ART) initiation or re-initiation with advanced HIV disease (AHD). The Zambia Ministry of Health (MOH) and other key stakeholders lack information about the characteristics and behaviors of AHD clients, including how they are defined and diagnosed (e.g. low CD4 count v. clinical condition), their demographic and socioeconomic profiles, their HIV care histories, what services they receive, and their short-term outcomes (achieve viral suppression, remain AHD, disengage from care, … |
THANDIWE NGOMA; | 2025-04-30 |
| 121 | Chikungunya Virus Detection in Semen: Preliminary Study – CHIKSPERM PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Chikungunya is an arboviral disease transmitted by Aedes mosquitoes, present in intertropical zones and Europe. In August 2024, autochthonous cases appeared on Réunion, followed by a large epidemic. In March 2025, the incidence surpassed 2,000 cases per week. Due to a lack of data, the Haut Comité de Santé Publique issued an unfavorable opinion on using substances of human origin during the epidemic. Although the presence of Chikungunya virus genome in semen has been reported in 7 men, the incidence of viral excretion is unknown. This raises concerns about the risk of sexual transmission and infectivity, … |
UNIVERSITY HOSPITAL TOULOUSE | 2025-05-21 |
| 122 | Phase 1, Open-Label, Randomised Crossover Study Assessing The Tolerability and Acceptability of Long Acting Cabotegravir Intramuscular and Lenacapavir Subcutaneous Injections Over Time in Healthy Adults Without HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the tolerability and acceptability of injection site reactions (ISRs) of two long-acting (LA) injectables. Additional characteristics of the ISRs will be investigated and described as well as safety outcomes. |
VIIV HEALTHCARE | 2025-11-28 |
| 123 | Single Center Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With Ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells for Immunodeficient Children and Young Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion. Secondary objectives are to determine the effect of R-MVST infusion on viral load, … |
PRAKASH SATWANI; | 2025-07-31 |
| 124 | A Pilot Randomized Controlled Trial and An Interview Study to Evaluate A Chatbot for People Living With HIV in Nigeria PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the use of a HIV chatbot that acts as an informational coach. The main question the study aims to answer is: Does the chatbot improve HIV knowledge in adults (older than 18-years) newly diagnosed with HIV in Nigeria – compared to a control group? Moreover, the study will also determine potential effects of the chatbot use on patients’ resilience, psychological well-being. The study will explore patients’ use and perceptions of the chatbot, … |
CHRISTOPH PIMMER; | 2026-01-23 |
| 125 | A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate A Switch to Islatravir (ISL) and Ulonivirine (ULO) Once Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it. |
MERCK SHARP & DOHME | 2025-10-16 |
| 126 | GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging Young African American Women in A Virtual Group App to Address Alcohol Misuse, Sexual Risk, and Pre-exposure Prophylaxis (PrEP) in North Carolina (NC) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this trial is to test a modified mobile health intervention (with a group component) relative to a mobile health intervention in a two-arm randomized trial with 500 young African American women who are human immunodeficiency virus (HIV)-negative and who misuse alcohol. The expected outcomes are to: (1) determine the efficacy of the virtual group component in reducing alcohol use and sexual risk and increasing pre-exposure prophylaxis (PrEP) utilization; and (2) understand selected outcomes for implementation. Participants will be randomized to receive either the mHealth app or the mHealth app plus the group component, … |
FELICIA A. BROWNE; | 2025-06-04 |
| 127 | A Phase IIa Randomized, Controlled, Open-label Clinical Trial to Assess The Efficacy, Safety, and Tolerability of The Investigational Medicinal Product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) Oral Capsules, As Well As to Determine The Optimal Dosage in The Treatment of Patients With Recurrent Diverticulitis (DIREBIOT) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Patients with diverticulitis experience a prolonged course of the disease and report a variety of physical, psychological and social symptoms, which highly impacts in their quality of life. Although antibiotic therapy has been the preferred treatment option for acute diverticulitis, it does not control the disease in 40 percent of the patients with complicated diverticulitis and 13 to 23 percent of the patients with non-complicated diverticulitis, which results in chronic and recurrent episodes of diverticulitis. As the episodes repeat, … |
JUAN OCAÑA JIMÉNEZ; | 2025-06-05 |
| 128 | INcentives and ReMINDers to Improve Long-term Medication Adherence PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, … |
SEBASTIAN LINNEMAYR; | 2025-09-11 |
| 129 | Examining Genetic Literacy and Numeracy in The General Population PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are: 1. Which visual aid most accurately show genetic risk? 2. How do people perceive risk related to genetic test results? 3. What factors are associated with people discussing their results with family? Participants will: 1. receive of of two visual aids showing risk 2. state their estimation of risk 3. answer questions about how they feel about risk and sharing information with family |
ANDREW DWYER; | 2025-04-02 |
| 130 | Safety, Tolerability and Effectiveness of DOlutegravir/Lamivudine Compared With Bictegravir/Tenofovir Alafenamide/Emtricitabine in People Living With HIV Without Antiretroviral Experience (TEOTL) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on the long-term adverse effects of antiretrovirals, especially integrase strand transfer inhibitors, as they have been associated with significant weight gain, which may be associated with increased cardiovascular risk. Objective: To determine the effectiveness, safety, and tolerability of Dolutegravir/Lamivudine (DTG/3TC) compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) in treatment-naive people living with HIV (PWH). Materials and methods: With prior approval from the Ethics and Scientific Research Committee 3502, an open-label, … |
JOSÉ ANTONIO MATA MARÍN; | 2025-06-26 |
| 131 | ANRS EP69 BICTEVOIR : A Prospective Study to Determine The Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated By A First Line Treatment Containing Bictégravir, Emtricitabine and Ténofovir Alafénamide PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of the study is to evaluate the diffusion of bictegravir and associated backbone (tenofovir alafenamide and emtricitabine) in HIV-1 chronic patients in the main putative reservoirs, namely inguinal lymph nodes, rectal, fat tissues and sperm. |
ANTOINE CHERET; | 2025-02-05 |
| 132 | Safety and Immunogenicity of Stabilized CH505 TF ChTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on study for up to 100 weeks (52 weeks on study treatment plus 48 weeks follow-up). |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-03-03 |
| 133 | Proof-of-Concept Study: Investigating The Impact of NMN Supplementation on CD4+ T Cell Recovery in Virologically Suppressed HIV Patients With Immunological Failure Related Papers Related Patents Related Grants Related Experts Highlight: This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. A small cohort of patients will be recruited to evaluate the primary outcome of change in CD4+ T cell count from baseline to the end of the study period after receiving NMN daily for 12 weeks. Secondary outcomes including safety and tolerability, … |
TRIHEALTH | 2025-04-03 |
| 134 | Effectiveness of Comprehensive Ending The Epidemic (ETE) Interventions in The Dental Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to use information technology (IT) to support the efficient delivery of HIV prevention and care best practices in the dental care setting. |
MICHAEL YIN; | 2025-07-23 |
| 135 | RV630 – Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for The Induction of HIV Remission PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI). |
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE | 2025-09-16 |
| 136 | PrEVE: Evaluation of The Acceptability and Impact of A Sexual Health Screening and Prevention Program for Vulnerable Women in The Greater Paris Region PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Globally, women accounted for more than half of people living with HIV (53%) in 2022. In France, 54% of new infections were heterosexual in 2022, 71% of whom were born abroad, mainly in sub-Saharan Africa (74%). Among women, 80% of new cases were born abroad, of which at least 30% contracted HIV after arriving in France, often in connection with social vulnerability as shown by the French study Parcours. In the Paris region, 1,243 new cases among women were registered between 2018 and 2021 (about 300 per year). Unstable housing, experiences of violence, … |
CENTRE DE RECHERCHES ET D’ETUDE SUR LA PATHOLOGIE TROPICALE ET LE SIDA | 2025-05-30 |
| 137 | Sustaining Healthy Choices: Optimizing A State-wide Scalable Intervention to Improve Alcohol and HIV Self-management in Adolescents and Emerging Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of PROJECT SUSTAIN is to optimize Healthy Choices to advance an adaptive and scalable intervention designed to improve self-management of alcohol and HIV in Young People with HIV (YPWH) while understanding the context for state-wide implementation and sustainment in a Hybrid Experimental Design (HED). SUSTAIN utilizes mHealth and telehealth intervention delivery of Healthy Choices (HC), combined with text messaging between sessions, to increase the likelihood of daily medication adherence (primary outcome), and increase the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3 (secondary outcome). |
SYLVIE NAAR; | 2025-04-30 |
| 138 | Mitigating The Impact of Stigma and Shame As A Barrier to Viral Suppression Among People Living With HIV and Substance Use Disorders PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: People living with HIV and substance use disorders (SUDs) are less likely to be virally suppressed, which can lead to HIV transmission and negative health outcomes. This hybrid type 1 study will assess the efficacy, mechanisms, as well as facilitators and barriers to implementing the MATTER intervention, a virtually delivered 5-session text-enhanced psychobehavioral intervention designed to facilitate viral suppression by addressing internalized stigma and shame as barriers to engagement in HIV care among individuals living with HIV and SUDs in two locations with different levels of HIV resources (i.e., the Boston, Massachusetts and Miami, … |
ABIGAIL BATCHELDER; | 2026-01-08 |
| 139 | PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: PrEP My Way is a novel PrEP delivery system consisting of clinic-based PrEP initiation, followed by peer-delivered kits for HIV self-testing, PrEP refills, vaginal swabs for gonorrhea and chlamydia self-sampling, pregnancy tests, and contraception refills, if desired. Based on Social Cognitive Theory, the overall hypothesis is that PrEP My Way will overcome critical stigma and structural barriers that currently limit PrEP use and thus empower young women to promote their sexual health. Preliminary testing of PrEP My Way in Kisumu, Kenya found it to be highly feasible and acceptable, … |
JESSICA HABERER; | 2025-03-19 |
| 140 | Real World Use of Lenacapavir, As An Add-on to An Optimized Background Regimen in France: A Retrospective Observational Study (LENAddOn) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: For most people with HIV (PWH), an effective antiretroviral regimen can be devised. However, some PWH have multiple treatment failures due to viral resistance or unacceptable side effects to medication and no longer have durable viral suppression. People with multidrug-resistant HIV-1 are at increased risk for hospitalization, progression to acquired immunodeficiency syndrome, and death. Lenacapavir (LEN) is a first-in-class capsid inhibitor and has been evaluated through the CAPELLA phase 3 trial in PWH with replicative multidrug-resistant HIV-1. In this trial, LEN combined with an optimized background regimen (OBR) led to high levels of viral suppression, … |
ROMAIN PALICH; | 2025-05-22 |
| 141 | A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose). |
OMAR HARFOUCH; | 2025-03-07 |
| 142 | Factors Associated With Advanced HIV Disease and Poor Nutrition Among People Living With HIV: A Hospital-based Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Aim of the work: 1. To determine the frequency of advanced HIV among PLWH in Assiut University Hospital. 2. To assess the nutritional patterns and frequency of poor nutrition among PLWH. 3. To evaluate factors associated with advanced HIV disease and poor nutrition among PLWH. |
SALMA HUSSEIN BADRY; | 2025-02-28 |
| 143 | A Phase I Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immediately to the University of Alabama at Birmingham (UAB) Pharmacokinetic Lab and processed in real time. Within = 7 days, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-04-03 |
| 144 | Universal Screening for Hepatitis Delta Virus (HDV) in Individuals Living with HIV/HBV Coinfection and HBV-related HCC PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC. |
GRACE LAI HUNG WONG; | 2025-03-24 |
| 145 | Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body’s immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells. |
ARIELA NOY; | 2026-02-09 |
| 146 | Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to achieve health equity in substance use disorder (SUD) screening and treatment among people living with human immunodeficiency virus (HIV) by implementing interventions to decrease barriers to screening (clinic-based, in-person) and treatment (referral-focused), a program the study investigators call Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use (ePORTAL HIV-S). The ePORTAL HIV-S randomized control trial will focus on portal-based screening in the HIV clinic, regardless of whether the patient has a scheduled appointment with their HIV provider. |
JESSICA P. RIDGWAY; | 2026-03-10 |
| 147 | A Clinical Study Evaluating The Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2025-09-29 |
| 148 | A Gender-Affirming Stigma Intervention to Improve Substance Misuse and HIV Risk Among Transgender Women PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is testing a new mutual-help group called the TLC program for transgender adults who use substances or are recently in recovery. The TLC Program is based on Acceptance and Commitment Therapy or ACT which is a type of mental health counseling that focuses on using mindfulness skills to connect a person to their values and improve their mental health. The TLC Program was developed by transgender and gender diverse community members, mental health providers, and researchers. |
ARRYN GUY; | 2026-03-27 |
| 149 | Development of A New Family of HIV Latency Regulators (LRAs) Targeting The Tat Viral Protein PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV. One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the shock-and-kill strategy, … |
UNIVERSITY HOSPITAL MONTPELLIER | 2025-02-24 |
| 150 | Impact of Two Types of Interventions (Ventrogluteal Versus Dorsogluteal Injection Site; Virtual Reality Headset: Presence or Absence) on Pain After Injections of Vocabria® (Cabotegravir) and Rekambys® (Rilpivirine) in Patients Infected With Human Immunodeficiency Virus -1 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®) in patients infected with HIV-1, depending on the injection site and whether or not they are wearing a virtual reality headset. The reference group being the dorsogluteal injection without headset. Participants who meet the study criteria will be randomized into 1 of 24 sequences. A sequence is composed by 4 injections procedures: dorsogluteal intramuscular injection (A), ventrogluteal intramuscular injection (B), dorsogluteal intramuscular injection with virtual reality headset (C), … |
DANIELA PIRES ROTEIA; | 2025-12-30 |
| 151 | Feasibility of Intravaginal Artesunate As Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to improve Human papillomavirus (HPV) treatment outcomes in Women Living with Human Immunodeficiency Virus (WLWH). The study will evaluate whether women who use artesunate will have higher HPV clearance at 6 months, compared to those who used a placebo. The study will also assess the safety, adherence, and acceptability of this treatment. 120 participants will be enrolled in the study. Participants will self-administer the study drug nightly for 5 days, take a week off, … |
CHEMTAI MUNGO; | 2025-12-17 |
| 152 | Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients Living With HIV-1 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the absence of surface antigenemia, HBsAg negativity, with the presence of HBV-core antibody, HBcAb) and switching from antiretroviral therapy (ART) including nucleos(t)ides to long-acting formulation. |
CASTAGNA ANTONELLA; | 2025-11-30 |
| 153 | Improving HIV Testing Among Children Under Five in Rural Uganda PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn if HIV screening testing can be done for children ages 18 months to 5 years by traditional healers in Southwestern Uganda. The main questions the investigators aim to answer are: * Will caretakers of children coming to a traditional healer for their care accept an HIV test from them? * What views of HIV such as stigma and knowledge might affect the caretaker’s choice to accept HIV testing or not for their child? Researchers will compare how many caretakers accept HIV testing for their child by a traditional healer compared to how many accept and go for testing at a nearby health center after being referred by a healer. Participants will: * Complete a form with the child’s health history and past medical history * Complete surveys on knowledge and understanding of HIV and stigma * Decide to to have a rapid, oral swab test the child-participant for HIV * Complete a follow up call once per month for 3 months to see if the child-participant went for follow up care for those in the referral group or for those who tested positive by the traditional healer |
ANNEKA HOOFT; | 2026-03-11 |
| 154 | A Phase 1 Single Arm, Repeat Dose Study to Evaluate The Pharmacokinetics, Safety, and Tolerability of Switching to Cabotegravir Ultra Long-acting From Cabotegravir Long-acting in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers. |
HARRY EARL STUDDARD; | 2025-02-19 |
| 155 | Adapting An Evidence-Based Intervention To Improve HIV Testing And PrEP Uptake In Vietnam PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Young men who have sex with men are experiencing an ongoing HIV epidemic in Vietnam, with an HIV prevalence of 12%. However, HIV testing and pre-exposure prophylaxis (PrEP) use among young men who have sex with men remain low. To improve HIV testing and PrEP use, mobile health (mHealth) interventions hold great promise to reach young men who have sex with men in low- and middle-income countries. HealthMindr, an evidence-based mHealth intervention developed in the United States for men who have sex with men, … |
XUAN BINH MINH NGUYEN; | 2025-08-22 |
| 156 | HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition. |
AMY C JUSTICE; | 2026-01-15 |
| 157 | Short-term Addition of Efavirenz to Induce CARD8-mediated Reduction of Persistent Nonsuppressible HIV Viremia in People With High Adherence to ART PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir. These cells carry infectious HIV capable of restarting HIV replication if therapy is stopped. The reservoir is so stable forcing people to adhere life-long ART. Over 5% of ART adherent individuals continue to have residual non-suppressive viremia (NSV) detected by clinical assays (40-400 copies/ml). Residual viremia reflects a more persistent reservoir and has the potential for increased morbidity. For eg., persistent expression of HIV proteins contributes to inflammation, … |
MARIO OSTROWSKI; | 2026-03-17 |
| 158 | Use of Long-Acting Injectable Cabotegravir/Rilpivirine for The Treatment of HIV in Belgium PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV Secondary outcomes • Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis |
RAKAN NASREDDINE; | 2025-02-05 |
| 159 | MyPEEPS LITE Trial PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=3,200), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary individuals that are assigned male sex at birth, … |
REBECCA SCHNALL; | 2026-02-27 |
| 160 | The Collaborative Care PrTNER (Prevention, Treatment, Navigation, Engagement, Resource) Project PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living with HIV) among young Black and Latino men who have sex with men (YBLMSM) aged 15 to 24 through engagement in SU treatment. |
RENATA SANDERS; | 2025-08-29 |
| 161 | PrEPARE-SCALE: Scaling Up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics for Pregnant and Postpartum Women PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This project aims to develop a community of practice; then test a combination of community of practice, quality improvement, and a training toolkit, to enhance implementation and clinical outcomes; and identify patterns attributes associated with successful implementation. |
ANJULI WAGNER; | 2026-01-30 |
| 162 | Development of A Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy. Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, … |
ANAIS CORMA-GOMEZ; | 2025-03-06 |
| 163 | A Phase 2b Single Arm, Repeat Dose Study to Evaluate The Pharmacokinetic Profile, Safety, and Tolerability of A New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition. |
VIIV HEALTHCARE | 2025-11-18 |
| 164 | An Integrated Intervention Using A Pill Ingestible Sensor System to Trigger Actions on Multifaceted Social and Behavioral Determinants of Health Among PLWH PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be randomized into intervention or usual care groups, with endpoints including intervention acceptability, SBDOH interventions, adherence to ART, viral load, and high-risk sexual activity. The study aims to assess the effectiveness of the integrated intervention in improving adherence, virologic outcomes, and reducing high-risk behavior among PLWH. |
HONGHU LIU; | 2026-02-13 |
| 165 | A Pilot Study to Evaluate The Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and saves lives. Nevertheless, ART cannot eradicate latent cellular reservoirs of the virus, and HIV-1 infection remains a life-long battle. Adoptive cellular immunotherapy using chimeric antigen receptor (CAR) engineered T cells directed against HIV-1 envelope subunit protein gp120 (HIVCAR T cells) may provide a safe and effective way to eliminate HIV-infected cells. However, the number of HIV-infected cells is low in participants under ART, … |
JOHN H. BAIRD; | 2026-02-23 |
| 166 | A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate The Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV. |
SHAWN SEARLE; | 2025-10-29 |
| 167 | Investigation of The Effects of Transtheoretical Theory-based Education Given to Individuals Followed in Amatem on Their Sexual Risk Taking, AIDS Knowledge Levels and Protection Self-efficacy: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The research was planned to examine the effect of the transtheoretic theory-based education given to individuals followed in AMATEM on their sexual risk-taking status, AIDS knowledge level and AIDS prevention self-efficacy. Research Hypotheses H0: Transtheoretical theory-based education given to individuals followed in AMATEM has no effect on their sexual risk taking, AIDS knowledge level and protection self-efficacy. H1-1: Transtheoretic theory-based education given to individuals followed in AMATEM has an effect on the level of sexual risk taking. H1-2: The transtheoretic theory-based education given to individuals followed in AMATEM is A |
HÜLYA İNCIRKUŞ KÜÇÜK; | 2025-08-28 |
| 168 | A Multicenter, Prospective, Cohort Study Evaluating The Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 – ADC joint PD – 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) the efficacy and safety. Indications: Trop2 – ADC joint PD – 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) treat above 2 late three negative breast cancer (TNBC). |
CHUNFANG HAO; | 2025-03-25 |
| 169 | Enhanced Diagnostic Workup for Patients About to Start Empiric Tuberculosis Treatment in Lusaka, Zambia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being conducted to determine whether in patients who are diagnosed with tuberculosis on a clinical basis (where tuberculosis is not found in the sputum) might have other lung diseases than tuberculosis. Depending on the precise nature of your complaints, additional investigations shall be requested by the study investigators. Possible additional investigations will include laboratory tests on samples of your blood, an additional chest X-ray, lung function testing (where you will have to blow air into a machine, so that your lung capacity is registered), CT-scan, … |
T.W. HOFFMAN; | 2025-07-14 |
| 170 | We Are Together (WAT): Development and Testing of An Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Purpose of this Study: The main purpose of this study is to adapt an existing evidence-based intervention, Project Accept Post-Test Support Services (PTSS) Module 3, specifically for pregnant and postpartum women living with HIV (WLWH) in Ghana. The adapted intervention aims to reduce HIV-related stigma and improve adherence to antiretroviral therapy (ART) and mental health symptoms, such as depression and anxiety, among this vulnerable population. Why was this study done? (Background): HIV-related stigma is a major obstacle for women living with HIV, particularly pregnant women in Sub-Saharan Africa (SSA), … |
JERRY J OUNER; | 2025-07-15 |
| 171 | Out-of-State, At-Home, Transcutaneous Auricular Neuromodulation for Hypermobile Ehlers Danlos Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Hypermobile EDS and hypermobile spectrum disorder (collectively referred to as hEDS) are estimated to affect 1 in 500 individuals worldwide. hEDS patients have limited treatment options for their numerous symptoms that impact the quality of life. This clinical trial tests a new ear stimulation method in hEDS patients to determine if it may improve quality of life. |
JEFFREY BORCKARDT; | 2026-02-27 |
| 172 | Know Your Status: A Cluster Randomized Controlled Trial Comparing Healer-initiated HIV Counseling and Testing to Standard of Care in Rural South Africa PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: South Africa has made progress towards their 95-95-95 goals, yet a substantial proportion of the population do not test regularly. To reach people who otherwise may avoid testing, we propose to build on our successful healer-initiated HIV counseling and testing pilot to conduct a cluster randomized controlled trial in 42 clinical catchment areas to evaluate an expanded Healer-Initiated HIV Testing and Linkage to Care intervention in rural South Africa. |
CAROLYN AUDET; | 2025-12-23 |
| 173 | TechMPower: Advancing HIV/SUD Care and Service Delivery for People Involved in The Criminal Legal System PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical study in one NY county is to pilot and refine implementation strategies aimed at improving delivery and uptake of evidence-based practices (EBPs) for HIV prevention/treatment and substance use disorder (SUD) care among incarcerated individuals approaching release with or at risk for HIV and SUD. The main questions it aims to answer are: 1. How feasible and acceptable are the TechMPower implementation strategies (community coalition workgroups, multidisciplinary implementation team with champion, … |
TIMOTHY HUNT; | 2026-02-18 |
| 174 | Structured Peer-delivered Antiretroviral Therapy (ART) and Reentry Community Strategy to Overcome Barriers to HIV Care Continuity During Community Re-entry From Incarceration in South Africa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The overarching goal of this study is to implement a transition community adherence club strategy (Full-SPARCS) for HIV-positive individuals transitioning from correctional to community settings in South Africa. The investigators seek to provide actionable findings to inform policy decisions to contribute to HIV care continuity with this population. The investigators note that effectiveness and scalability often conflict with intervention design; thus, … |
CHRISTOPHER HOFFMANN; | 2026-02-11 |
| 175 | A Prospective Study of HIV+ Deceased Donor Heart Transplant for HIV+ Recipients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a prospective single-center interventional trial to compare the outcomes of HIV-positive heart transplant recipients by the HIV status of the donor; HIV-positive vs. HIV-negative and learn whether heart organ transplantation from HIV+ deceased donors is as safe and effective in HIV+ recipients as transplants from HIV- deceased donors. Patient will undergo standard evaluation for eligibility of transplantation by the primary heart transplant team. If patient meets eligibility criteria, … |
RICARDO LA HOZ; | 2026-01-21 |
| 176 | Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies (LiVes LLC Study) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine both Human papillomavirus (HPV) vaccine effectiveness and Primary high-risk HPV PHS screening triage strategies in women living with HIV (WLHIV) by partnering with the Pediatric HIV/AIDs Cohort Study (PHACS) led, in part, by our investigative team. Among WWH, … |
ANNA-BARBARA MOSCICKI; | 2025-08-29 |
| 177 | Cancer Prevalence and Outcomes in Individuals Living With HIV and AIDS: Multicenter BUHASDER Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: AIDS-defining cancers reported a 70% drop in the 1990s following the advent of triple antiretroviral therapy in the USA. With increased survival, the proportion of non-AIDS-defining cancers increases with age, making cancer a leading cause of death among individuals with HIV infection in developed countries, with higher cancer-related mortality rates in this group. In Turkey, studies have reported HIV-associated non-Hodgkin lymphoma cases, and a multicentre study documented 37 cancer cases from 1998 to 2016. This study aims to determine the prevalence of cancer in individuals with HIV and AIDS in Turkey over the past decade, … |
ÖZLEM GÜLER; | 2025-04-24 |
| 178 | Empathy in Frames: Assessing The Impact of Ethnic Concordance in Animated Cartoons on HIV/AIDS Stigma Among South African Young Adults PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study looks at whether using cartoons that reflect the culture of South Africa can help change how young adults there think about HIV/AIDS. This study will test two types of cartoons in a two-arm (treatment, comparator) randomized controlled trial design-one with Black characters and one with White characters-to see how they affect people’s attitudes and knowledge about HIV/AIDS. Randomly allocated participants will be Black seronegative South African adults between 18 and 35 years old. This group was chosen because they’re a demographic disproportionately affected by HIV, they’re at a high point in their lives for shaping and sharing beliefs, … |
YANIS BEN AMOR; | 2025-02-19 |
| 179 | Strategies to AchieVe Viral Suppression for Youth With HIV (The SAVVY Study) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, … |
ALLISON AGWU; | 2026-02-04 |
| 180 | FINISHING HIV: An Ending The HIV Epidemic (EHE) Model for Latinx Integrating One-Stop-Shop Pre-Exposure Prophylaxis (PrEP) Services, A Social Network Support Program and A National Pharmacy Chain PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to learn how to help enable healthy behaviors and lower the risk of HIV among Latinx Men. |
MARIANO JUAN KANAMORI NISHIMURA; | 2026-03-24 |
| 181 | Enhancing HIV Prevention and Treatment Referral and Engagement Among Latino Men Who Have Sex With Men (MSM): A Pilot Hybrid Effectiveness-Implementation Trial of The JUNTOS Referral Network PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to evaluate the JUNTOS Referral Network as an implementation strategy to enhance the reach of HIV-prevention and treatment services to Latino gay, bisexual, and other men who have sex with men (MSM). |
AUDREY HARKNESS; | 2026-02-20 |
| 182 | Evaluating Novel Pediatric Pulse Oximeters for Outpatient Child Pneumonia Care in Sub-Saharan Africa PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this clinical trial is to evaluate the performance of three pulse oximeters during outpatient care within Cape Town, South Africa. This objective will be achieved through generating evidence on how, why, for whom, … |
ERIC MCCOLLUM; | 2025-12-03 |
| 183 | Presence of HIV-1 DRMs As A Risk Factor of Failure of Two Drugs Based ART Regimens, Including LAI ART, in Cohorts of Primary and Secondary DRMs PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The presence of drug resistance mutations (DRMs) in HIV plays an important role in ART effectiveness. Despite very good results of ART, there is constant concern about the emergence of HIV strains with DRMs, what may lead to virological suppression failure. The concerns grow especially among patients treated with two drugs based regimens, including long acting therapies in injections (LAI ART) or regimens used in preexposure prophylaxis (PreP). |
ANDRZEJ ZAŁĘSKI; | 2024-12-30 |
| 184 | The Relationship Between Anal High-Risk HPV (Hr-HPV) Infection, Anal High-Grade Squamous Intraepithelial Lesions (HSIL), and The Anal Microbiome Among Three Distinct Populations of Hispanic People Living With HIV (PLWH) in California, Mexico and Puerto Rico PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous intraepithelial lesions or HSIL) in Hispanic people living with HIV (PLWH) in Puerto Rico, Mexico and California |
JOEL PALEFSKY; | 2025-12-10 |
| 185 | Selection of Resistant Mutations to Dolutegravir and Associated Drugs in PLWH Treated in Clinical Practice in Chokwé, Mozambique PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection. |
FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | 2025-05-15 |
| 186 | Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis. |
CLAUDE CAPRON; | 2025-03-20 |
| 187 | Using Multiphase Optimization Strategy (MOST) to Optimize A Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study’s long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV. |
JENNIFER CANTRELL; | 2025-06-05 |
| 188 | Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination. |
RUANNE BARNABAS; | 2026-01-12 |
| 189 | VRC 617: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety and Pharmacokinetics of A Human Bispecific Antibody, VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: HIV (human immunodeficiency virus) is the virus that causes AIDS (acquired immunodeficiency syndrome). Researchers want to find new ways to treat or prevent HIV infection. CAP256J3LS is a new product that uses antibodies. Antibodies are naturally occurring proteins; … |
LASONJI A HOLMAN; | 2026-03-23 |
| 190 | A Family-Based HIV Prevention Program for Black Men to Protect Black Girls PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls’ sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence. |
NATASHA CROOKS; | 2025-05-08 |
| 191 | Pilot Testing of A Patient-provider Decision Aid for HIV Post-exposure Prophylaxis Following Sexual Assault PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this trial is to pilot a digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored multimedia-based HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being – I want to do everything I can to prevent HIV, privacy – I don’t want others to know about the exposure, or cost – I can’t afford the pills”) completed by patients; … |
JOCELYN ANDERSON; | 2025-07-18 |
| 192 | A Phase 1, Open-Label, Study of The Safety and Pharmacokinetics of A Human Monoclonal Antibody, VH4527079, Administered Either Intravenously or Subcutaneously to Healthy Adults and Persons With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH). |
VIIV HEALTHCARE | 2026-03-06 |
| 193 | Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison. The study is being conducted in nine federal prisons, including five women’s prisons, where a higher proportion of incarcerated individuals report a history of injection drug use. This study aims to improve PNEP adoption and sustainability by identifying barriers and facilitators and implementing evidence-based strategies to enhance program engagement. |
NADINE KRONFLI; | 2025-12-29 |
| 194 | Intervention to Enhance Prep Persistence Among African American Men Who Have Sex with Men PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators will conduct a fully powered randomized controlled trial (RCT) to test the effect of a patient navigation intervention for Black/African American (B/AA) men who have sex with men (MSM) on PrEP initiation, adherence and retention in care. B/AA men who have sex with men (MSM) are disproportionately impacted by the HIV/AIDS epidemic in the United States. Pre-exposure prophylaxis (PrEP), a once daily medication, can dramatically reduce HIV acquisition risk. However, social and structural barriers have contributed to suboptimal PrEP initiation, adherence, and retention in care among B/AA MSM. Our prior NIH-funded pilot study (R34MH109371; MPI: Nunn, Chan, … |
AMY NUNN; | 2025-03-12 |
| 195 | ORCHID: A Novel Positive Affect Intervention for Aging, Racial/Ethnic Minoritized Women With HIV (Miami) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this research is to test ORCHID (Optimizing Resilience \& Coping with HIV through Internet Delivery), a skills-building intervention that improves mental health status for persons with HIV, who are at-risk for falling out of care. |
LUNTHITA M. DUTHELY; | 2026-03-19 |
| 196 | Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face challenges in accessing healthcare services. In response, … |
REBECCA SCHNALL; | 2025-03-21 |
| 197 | By Assessing The Continuous Respiratory Physiological Changes Through Prone Position, Determine The Optimal Duration for Prone Position PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The prone position leads to a more homogeneous distribution of ventilation by inflation of collapsed alveoli and reduction in alveolar hyperinflation. By employing EIT, the study can obtain a thorough comprehension of the ongoing alterations in regional ventilation before and after adopting the prone position. It is also anticipated that there is an impact on inflammation biomarkers before and after the prone position. This assessment aids in determining the ideal duration for prone position therapy, encompassing the necessary hours and days in the prone position. |
TING-YU LIAO; | 2025-02-19 |
| 198 | A Phase 1, First-in-human, Open-label Study to Evaluate The Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of The Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). |
MICHAEL BIRRER; | 2026-02-11 |
| 199 | A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess The Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection. |
GLAXOSMITHKLINE | 2026-02-04 |
| 200 | Comparison of The Response and Pathomechanism of Purified Tuberculin Unit Protein Injection Therapy for Anogenital Warts with and Without HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Warts are a common viral infection of the skin and are prevalent throughout the world, with an overall prevalence in the United States estimated at 2-20%. The incidence of anogenital warts occurs more frequently in HIV-infected patients, with a seven-fold increase in risk compared to patients without HIV infection. Available treatments for anogenital warts can only reduce, but cannot eradicate, HPV infection. There are many therapeutic options for treating anogenital warts, but none can prevent recurrence. Immunotherapy has become one of the best therapeutic options for warts caused by HPV infection because it increases the immune response to HPV infection, … |
UNIVERSITAS PADJADJARAN | 2025-12-31 |